Wednesday, 7 June 2017

Cancer Monoclonal Antibodies Market is Expected to Grow at a CAGR of 10.86% By 2021

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects.

Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics. The report analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021.

Covered in this report:

The report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
Cancer Monoclonal Antibodies Market has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors ?operating in this market.

Key vendors
  • F. Hoffmann-La Roche
  • Amgen
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals
Other prominent vendors
  • AbbVie
  • ADC Therapeutics
  • Agensys
  • Argos Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • BioGenomics
  • Boehringer Ingelheim
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • CTI BioPharma
  • Daiichi Sankyo
  • Eli Lilly
  • Fortress Biotech
  • Genmab
  • Immunomedics
  • Intas Pharmaceuticals
  • Janssen Biotech
  • Kyowa Hakko Kirin
  • Merck
  • MedImmune
  • Morphotek
  • Neovii Biotech
  • Novartis
  • OncoMed Pharmaceuticals
  • Pfizer
  • Sanofi
  • Seattle Genetics
  • TG Therapeutics
  • Xbiotech
Market driver
  • Increase in demand for ADCs
  • For a full, detailed list, view our report
Market challenge
  • Complicated regulatory framework
  • For a full, detailed list, view our report
Market trend
  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors ?
  • What are the strengths and weaknesses of the key vendors ?

No comments:

Post a Comment